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Stem cells, by definition, are able to both self-renew (give rise to more cells of their
own kind) and demonstrate multipotential (the ability to differentiate into multiple cell
types). To accommodate this unique dual ability, stem cells interpret signal transduction
pathways in specialized ways. Notable examples include canonical and non-canonical
branches of the Notch signaling pathway, with each controlling different downstream
targets (e.g., Hes1 vs. Hes3) and promoting either differentiation or self-renewal. Similarly,
stem cells utilize STAT3 signaling uniquely. Most mature cells studied thus far rely
on tyrosine phosphorylation (STAT3-Tyr) to promote survival and growth; in contrast,
STAT3-Tyr induces the differentiation of neural stem cells (NSCs). NSCs use an alternative
phosphorylation site, STAT3-Ser, to regulate survival and growth, a site that is largely
redundant for this function in most other cell types. STAT3-Ser regulates Hes3, and
together they form a convergence point for several signals, including Notch, Tie2, and
insulin receptor activation. Disregulation and manipulation of the STAT3-Ser/Hes3 signaling
pathway is important in both tumorigenesis and regenerative medicine, and worthy of
extensive study.
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ENCODING MULTIPLE FUNCTIONS WITHIN THE COMMON
SIGNALOSOME
Stem cells exhibit the fundamental properties of both self-renewal
and differentiation into multiple cell types. The balance between
these two must be finely regulated in order to allow stem cells
to properly contribute to tissue formation during development
and later, in the context of resisting degenerative disease and
normal wear-and-tear as we age. Key to this balance is the
clear allocation of these two functions to distinct signal trans-
duction pathways. Nature had two options to accomplish this
task: (a) to put aside part of the signaling machinery to be
used exclusively for self-renewal while have another totally sep-
arate set for regulating their multipotential nature, or, (b) to
have individual cell types interpret the same signaling pathways
differently. In the latter case, a stem cell could, for example,
co-opt some typically pro-survival pathways, and utilize them
as pro-differentiation signals. Consequently, a stem cell would
have fewer pro-survival choices, but it would also be able to
encode its multipotential nature without the need for possess-
ing a unique set of signaling molecules. A specific example
highlighting the second option is a signal transduction path-
way that is emerging as a convergence point for diverse signals
and regulates self-renewal vs. differentiation decisions with con-
sequence in regenerative medicine, cancer biology, and drug
discovery strategies. At the center of this pathway is the phos-
phorylation of Signal Transducer and Activator of Transcription
3 (STAT3) on the serine residue at amino acid position 727
(STAT3-Ser) and subsequent induction of the transcription
factor Hairy and Enhancer of Split 3 (Hes3), a member of the
Hes/Hey gene family of basic helix-loop-helix (bHLH) transcrip-
tion factors.
THE NEGLECTED STAT3-Ser
The Janus kinase (JAK)-STAT pathway is a major, evolutionarily
conserved signaling component in the cells of many organisms,
ranging from slime molds to humans. Like other signal trans-
duction cascades, its role is to convey information from the cell’s
environment all the way to DNA promoters on the genome,
resulting in changes in gene expression. Binding of ligands, such
as cytokines, hormones and growth factors to surface receptors
leads to activation of JAKs. JAK proteins are a family of non-
receptor tyrosine kinases and their most prominent targets are
STAT proteins. Tyrosine-phosphorylated STATs then enter the
nucleus where they regulate gene transcription. The long evo-
lutionary history of the JAK-STAT pathway has incorporated
it into many other signaling pathways making it relevant to a
vast array of intrinsic and environmental stimuli, cell prolifer-
ation, development, hematopoiesis, immunity, metabolic regu-
lation, and cancer (Levy and Darnell, 2002; Shen et al., 2004;
Richard and Stephens, 2011; Vera et al., 2011; Wauman and
Tavernier, 2011; Camporeale and Poli, 2012; Lafave and Levine,
2012; Mohr et al., 2012; O’shea and Plenge, 2012; Stark and
Darnell, 2012; Tibes et al., 2012; Swiatek-Machado and Kaminska,
2013).
In addition to the tyrosine phosphorylation site, some STAT
proteins also have a serine phosphorylation site (Decker and
www.frontiersin.org October 2013 | Volume 4 | Article 273 | 1
Poser et al. The STAT3-Ser/Hes3 signaling axis
Kovarik, 2000; Reich, 2009). STAT-Ser phosphorylation is reg-
ulated by different pathways among STAT family members, as
demonstrated by pharmacological approaches using receptor lig-
ands and inhibitors of intracellular kinase cascades. In the case of
STAT3, serine phosphorylation is induced by EGF, PDGF, insulin,
IL-2, BCR, and TCR. In all these cases, STAT3-Ser phosphoryla-
tion is reduced by treatment with aMEK1/2 inhibitor (PD98059).
In contrast, when STAT3-Ser phosphorylation is induced by
treatment with IL-6 or IFN-alpha, phosphorylation is sensitive
to a broad spectrum kinase inhibitor, H7 (Chung et al., 1997;
Ng and Cantrell, 1997; Stephens et al., 1998; Su et al., 1999;
Decker and Kovarik, 2000). Adding to the complexity of STAT-
Ser phosphorylation regulation, multiple pathways activated by
the same receptor impinge upon different STAT-Ser phosphory-
lations, adding to the complexity, as well as the utility, of STAT3
in regulating discrete biological processes (Kovarik et al., 1999;
Lim and Cao, 1999; Decker and Kovarik, 2000). It will be highly
informative to extend such studies using cells from different
origins, and address how the regulation of STAT-Ser phospho-
rylation is affected by cell type, providing an additional level
of specificity in terms of pharmacologically manipulating this
site.
Early studies demonstrated that the role of STAT-Ser
phosphorylation is largely auxiliary to the function of
tyrosine-phosphorylated STAT3, resulting in an increase of
its transcriptional activity (Levy and Darnell, 2002). More recent
studies have uncovered potentially STAT-Ser—specific effects
on cell growth. In this article we will focus on STAT3 because
it is extensively studied in terms of its role in regulating the
self-renewal and differentiation of neural stem cells (NSCs).
In these cells, JAK2 phosphorylates STAT3-Tyr in response
to the activation of several receptors, including the CNTF
receptor. Tyrosine-phosphorylated STAT3 directly stimulates
transcription of genes expressed in astrocytes, most notably
glial GFAP, thereby promoting loss of the self-renewal state and
differentiation toward the astroglial fate (Bonni et al., 1997; Rajan
and McKay, 1998; Panchision and McKay, 2002). STAT3-Tyr
phosphorylation is undetectable during self-renewal, showcasing
its powerful role in inducing differentiation. This prompted
the question of whether STAT3 is irrelevant to NSC growth,
or whether NSCs utilized STAT3-Ser for regulating prolifera-
tion. Pharmacological and genetic (STAT3 phosphomimetic)
approaches demonstrate that STAT3-Ser, in the absence of
STAT3-Tyr, is a potent stimulator of NSC survival and growth
(Androutsellis-Theotokis et al., 2006).
Many reports today implicate STAT3-Ser in cell growth,
proliferation, and survival, in the context of cancer (Plaza-
Menacho et al., 2007; Qin et al., 2008; Aggarwal et al., 2009;
Lacreusette et al., 2009; Yeh et al., 2009; Banerjee et al., 2010;
Sekine et al., 2011; Villalva et al., 2011; Miyakoshi et al.,
2012; Tkach et al., 2013; Yang et al., 2013), insulin and
neurotrophin signaling (Ng et al., 2006; Kim et al., 2009),
neurite outgrowth (Zhou and Too, 2011), and hypertension
(Zouein et al., 2013). An extensively studied aspect of STAT3
that is dependent upon serine phosphorylation is its involve-
ment in the regulation of cellular respiration by localizing to
the mitochondrion where it regulates reactive oxygen species
production and cell death (Zhang et al., 2003; Shulga and
Pastorino, 2012).
In this article, we address a particular branch of the signal-
ing pathway involving STAT3-Ser and its downstream mediator,
the transcription factor Hes3. This STAT3-Ser/Hes3 Signaling
Axis does not operate in parallel to JAK-STAT, nor is it an
auxiliary to it. In fact, STAT3-Tyr and STAT3-Ser represent
distinct and opposing functions with significant consequences
for cellular function and fate determination. Here we dis-
cuss its involvement in neuro-regenerative medicine as well
as open questions that need to be addressed in order to ele-
vate our understanding of this pathway toward therapeutic
benefit.
Hes3: A SPECIALIZED MEMBER OF THE Hes/Hey GENE
FAMILY
The Hes/Hey family of bHLH transcription factors is a major tar-
get of the Notch signaling pathway (Artavanis-Tsakonas et al.,
1999; Imayoshi and Kageyama, 2011; Ueo et al., 2012). They
are expressed in NSCs and progenitor cells in vitro and in vivo,
where they repress the expression of genes involved in differ-
entiation, making them critical mediators of fate choice (Sasai
et al., 1992; Lobe, 1997; Allen and Lobe, 1999; Hirata et al.,
2001; Hatakeyama et al., 2004; Androutsellis-Theotokis et al.,
2006, 2008a,b, 2009, 2010a,b; Basak and Taylor, 2007, 2009;
Rueger et al., 2010; Imayoshi and Kageyama, 2011; Masjkur
et al., 2012; Pacioni et al., 2012). Different experimental sys-
tems seem to regulate which Hes/Hey family members are more
prominently expressed or modulated. For example, Hes1 opposes
neuronal differentiation and therefore may support the mainte-
nance of NSCs during mouse development (Hatakeyama et al.,
2004; Imayoshi and Kageyama, 2011; Shimojo et al., 2011; Tan
et al., 2012). Hes5 is expressed in multipotent progenitors in
the embryonic neural tube as well as in neurospheres generated
from this region in vitro (Hatakeyama et al., 2004; Basak and
Taylor, 2007). In monolayer cultures of fetal and adult mouse
NSCs, all family members are expressed (Androutsellis-Theotokis
et al., 2006). However, upon Notch activation by treatment
of the NSC cultures with a soluble form of the Notch recep-
tor ligands Delta4 or Jagged1, only Hes3 exhibits changes in
its expression (mRNA levels increases within 30min, peaking
at 1 h).
It is quite likely, therefore, that several Hes/Hey family mem-
bers may promote distinct functions in NSCs, or they may
cooperate with others. For example, combined deletions of Hes1,
Hes3, and Hes5 in mice leads to the depletion of progenitor cells
(Hatakeyama et al., 2004; Imayoshi and Kageyama, 2011).
Our understanding of the function of different Hes/Hey
genes received a great boost through the realization that differ-
ent branches of the STAT3 signaling pathway regulate and/or
involve distinct members of their family. For example, Hes1
and Hes5 form complexes with JAK2, promoting its ability
to phosphorylate STAT3-Tyr (Kamakura et al., 2004). In this
way, Hes1 and Hes5 are part of the pro-differentiation program
in cultured NSCs, resulting in increased astrocyte generation.
This is consistent with the in vivo observations showing that
Hes1 and Hes5 oppose the acquisition of the neuronal fates.
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However, the question remains open as to the extent to which
the Hes1+/Hes5+ cell population in the brain is undifferen-
tiated (i.e., are these NSCs, or more differentiated intermedi-
ates)? Alternatively, the NSC population may be defined as the
Hes1+/Hes5+/Hes3+ population. This is consistent with the
observations that Hes3 expression in NSC cultures is opposed
by JAK activity and supported by various treatments that pro-
mote STAT3-Ser phosphorylation (Androutsellis-Theotokis et al.,
2006, 2008b, 2009, 2010a,b). In fact, Hes3 can be used as a
NSC biomarker in vitro because it is expressed in NSCs and
lost upon induction of differentiation. In vivo, Hes3+ cells are
found in the established neurogenic zones (subventricular zone,
dentate gyrus) as well as many other areas of the adult brain;
these can be microdissected and cultures can be established
efficiently, demonstrating the NSC properties of Hes3+ cells
(Poser and Androutsellis-Theotokis, 2013). Hes3 being down-
stream of STAT3 is consistent with the observation that, unlike
Hes1 and Hes5, Hes3 is not a direct transcriptional target of
Notch (Kageyama et al., 2005). Together, these results establish
that activation of pathways resulting in STAT3-Ser phosphory-
lation has functions distinct from those of simply supporting
JAK-STAT (Figure 1A).
ACTIVATING THE STAT3-Ser/Hes3 SIGNALING AXIS
The role of the STAT3-Ser/Hes3 signaling axis in controlling NSC
number in vitro and in vivo makes it a potential pharmacological
target in neurodegenerative disease therapy (Kittappa et al.,
2012). Several diverse treatments that promote the pathway
exhibit similar results on cultured cell number, including ligands
of the Notch (Delta4, Jagged1) and Tie2 (Angiopoietin 2) recep-
tors, basic FGF, and insulin (Androutsellis-Theotokis et al., 2006,
2008b, 2009, 2010a,b). In vivo, Delta4, Angiopoietin 2, insulin,
or a combination of these along with an inhibitor of JAK sig-
nificantly increase the number of endogenous NSCs, establishing
the predictive properties of these culture systems (Androutsellis-
Theotokis et al., 2008a; Poser and Androutsellis-Theotokis,
2013). These factors also have known effects on blood vessels
with, Angiopoietin 2 promoting angiogenesis whereas Delta4
FIGURE 1 | (A) Different phosphorylation sites on STAT3 mediate canonical
and non-canonical functions of the Notch signaling pathway. In canonical
Notch signaling, the cleaved intracellular domain of the Notch receptor
translocates to the nucleus where it regulates transcription of target genes,
including Hes1 and Hes5. Hes1 and Hes5 are transcription factors
themselves and can therefore regulate additional target genes downstream
of Notch activation. However, they also have cytoplasmic functions where
they form complexes with JAK2 promoting its ability to phosphorylate
STAT3-Tyr (Kamakura et al., 2004). This modification leads to the induction of
differentiation in NSCs (Bonni et al., 1997). A non-canonical branch of Notch
signaling leads to STAT3-Ser phosphorylation in the absence of detectable
STAT3-Tyr phosphorylation (Androutsellis-Theotokis et al., 2006). This is
followed by increased transcription of Hes3. Hes3, in turn, promotes growth
through poorly understood mechanisms. A clue as to the function of Hes3
comes from observations that force-expressed Hes3 in NSC cultures
increases the expression of sonic hedgehog (Androutsellis-Theotokis et al.,
2006), a morphogen that also acts as a mitogen for NSCs (Ahn and Joyner,
2005). (B) Different cell types interpret STAT3 and Hes/Hey signaling in
specific ways. Many mature cell types (e.g., neurons and astrocytes in the
brain), as well as many established cell lines from different tissues utilize the
JAK/STAT pathway that leads to STAT3-Tyr phosphorylation for growth. In
contrast, STAT3-Ser phosphorylation is only auxiliary to the transcriptional
strength of STAT3 and dispensable. NSCs interpret these signals in a
different way. The JAK/STAT pathway involving STAT3-Tyr phosphorylation
induces their differentiation, preferentially to the astrocytic fate. NSCs can
now recruit the STAT3-Ser phosphorylation as a critical regulator of growth.
An important mediator of STAT3-Ser action is Hes3. Cancer stem cells (from
glioblastoma multiforme) are able to grow utilizing either the JAK-STAT or the
STAT3-Ser/Hes3 signaling pathways. The ability of cancer stem cells to grow
utilizing distinct signaling pathways blurs the line distinguishing cancer stem
cells from more differentiated cancer cells and underlines their ability to
evade therapy aimed at disrupting one or a limited set of signaling pathways.
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opposes it (Maisonpierre et al., 1997; Yancopoulos et al., 2000;
Noguera-Troise et al., 2006; Hellstrom et al., 2007; Siekmann
and Lawson, 2007; Thurston et al., 2007). Together, their antag-
onistic effects would mitigate any large scale changes in the
vasculature that results from their combined therapeutic use,
while still yielding a substantial increase in the number of
NSCs.
The observation that distinct phosphorylation sites on STAT3
mediate different outputs (Figure 1B) allows for testable pre-
dictions and the generation of new potential treatments based
upon an understanding of a given cell’s state. In the context
of NSCs for example, CNTF, through its activation of both
the JAK-STAT and phosphoinositide 3’ kinase (PI3K) path-
ways, leads to STAT3-Tyr phosphorylation as well as STAT3-
Ser phosphorylation (via activation of mTOR) (Decker and
Kovarik, 2000; Yokogami et al., 2000; Levy and Darnell, 2002).
JAK-STAT activation by CNTF is responsible for the power-
ful differentiation effect of CNTF toward the astrocytic fate.
Our understanding of STAT3 signaling allowed us to pre-
dict that concomitant treatment of NSCs with CNTF and a
JAK inhibitor would suppress STAT3-Tyr phosphorylation while
maintaining STAT3-Ser phosphorylation, thus converting the
culture conditions from pro-differentiation to pro-self-renewal
(Androutsellis-Theotokis et al., 2008b).
TAKING ADVANTAGE OF THE STAT3-Ser/Hes3 SIGNALING
AXIS
The consequences of activating the STAT3-Ser/Hes3 Signaling
Axis in vivo revealed new aspects of the regenerative/repair
potential of the adult mammalian central nervous system. First,
immunohistochemical detection revealed Hes3+ cells through-
out the adult rat brain, with the highest densities being found in
the subventricular zone lining the lateral ventricles and the den-
tate gyrus of the hippocampus (Androutsellis-Theotokis et al.,
2006, 2009). This is entirely consistent with a putative role
of Hes3 as a biomarker of endogenous NSCs/progenitor cells.
However, Hes3+ cells were also observed scattered through-
out many gray and white matter areas, displaying a charac-
teristic morphology and associating closely with blood vessels.
Microdissection of brain and spinal cord areas and subsequent
culture at clonal densities demonstrated the growth of Hes3+
cells and their differentiation to neurons, astrocytes, and oligo-
dendrocytes. Robust cultures can be established, taking advantage
of the signaling pathway and providing the culture medium
with ligands of the Notch and Tie2 receptors (Androutsellis-
Theotokis et al., 2008a; Poser and Androutsellis-Theotokis, 2013).
Using these cultures, self-renewal and multipotential of Hes3+
cells can be demonstrated (Androutsellis-Theotokis et al., 2009,
2010a,b).
When these factors are injected into the lateral ventricles
of rodents, the number of Hes3+ cells in many areas of
the brain and spinal cord increases within days, and results
in strong behavioral recovery in models of ischemic stroke
and Parkinson’s disease. (Androutsellis-Theotokis et al., 2006,
2008b, 2009; Masjkur et al., 2012; Pacioni et al., 2012). This
benefit occurred in the absence of detectable newly gener-
ated and matured neurons, suggesting these cells provide a
neuroprotective effect through trophic support rather than
outright replacement. Indeed, in the Parkinsonian models,
nigrostriatal dopamine neurons that would otherwise have
been lost were rescued. These results revealed a mechanism
that the adult central nervous system operates for damage
repair, coupling vascular signals (e.g., Delta4, Angiopoietin 2)
and a widespread multipotent precursor cell to establish
a regenerative environment that promotes restoration of
function.
As an extension of these observations, carcinogenesis is some-
times viewed as the manifestation of aberrant regenerative
mechanisms. The cells that carry the regenerative ability of a
tumor, termed cancer stem cells, express genes common to their
non-cancerous stem cell counterparts (Hanahan and Weinberg,
2011; Poser et al., 2011). In line with this notion, putative cancer
stem cells from the aggressive brain tumor glioblastoma mul-
tiforme express Hes3 both in the patient and in culture. Hes3
RNA interference results in increased death in cells isolated from
patient biopsies (Park et al., 2013), highlighting another poten-
tial therapeutic benefit of targeting the STAT3-Ser/Hes3 Signaling
Axis.
CONCLUSIONS
In the 1960s, Joseph Altman’s experiments demonstrated,
through the use of tritiated thymidine, that the adult mam-
malian brain contains proliferating cells that can become neurons
(Altman and Das, 1965). It took decades to begin appreciat-
ing the significance of these findings and eventually a vigorous
search started for biomarkers to identify this cellular popu-
lation. The results of this effort uncovered discrete regions
that harbor multipotent progenitor cells, the stem cell niches
of the subventricular zone and the dentate gyrus. However,
the bias of the search toward proliferating (albeit slowly) cells
resulted in the field missing the widespread neural stem cell
population that may be largely quiescent, possibly not even
being able to generate new neurons in their microenvironment
in vivo, but nevertheless, are just as critical to the mainte-
nance of the brain as we age, or recover from injury. The rea-
son for the existence of these “parenchymal” stem cells is not
clear but it is conceivable that they are the result of an evo-
lutionary adaptation toward brain tissue rigidity, as a means
of storing information and lessons learned as the extraor-
dinary regenerative plasticity that lower animals exhibit may
be incompatible with long-term memory storage. These cells
may have kept some of their progenitor character (e.g., some
biomarkers) but have adapted from direct cell replacement to
modulating the microenvironment, thus playing a neuropro-
tective role. In this way, these cells can still contribute to tis-
sue repair without interfering with information storage. This
may also be an evolutionary adaptation because as the mam-
malian brain has grown large, the challenge of new neurons
efficiently recapitulating lost neuronal connections has become
extremely daunting. This problem is encountered by efforts to
replace lost neurons using approaches that involve the grafting
of exogenous NSCs or fetal neuronal tissue. Just like placing a
bunch of cable bits in a broken computer does not guarantee
that the computer will work again, there is still work to be
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done before we understand how to effectively integrate a graft
bolus into the appropriate brain circuitry to facilitate recovery.
Until then, boosting natural, innate repair mechanisms, such as
those involving the STAT3-Ser/Hes3 Signaling Axis, represents a
sound strategy that both seems to work and addresses disease
progression.
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